Cardiac fibrosis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Angiotensin II stimulates cardiac fibrosis and conduction heterogeneity.
|
19648063 |
2009 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease.
|
20157054 |
2010 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis.
|
23337087 |
2013 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with anti-IL-16 neutralizing antibody ameliorated cardiac fibrosis in the mouse model of angiotensin II-induced hypertension.
|
23894370 |
2013 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-29b plays a protective role in AngII-mediated cardiac remodeling and may be a therapeutic agent for cardiac fibrosis by targeting the TGF-β/Smad3 pathway.
|
24569834 |
2014 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.
|
25898844 |
2015 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
28474247 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that macrophages when recruited into the heart and aorta from the spleen potentially contribute to angiotensin II-induced cardiac fibrosis and hypertension.
|
28490219 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling.
|
28944921 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erratum to: Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
29030734 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice in which αv integrin is depleted in PDGFRβ<sup>+</sup> cells are protected from cardiotoxin and laceration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis.
|
29061963 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-to-mesenchymal transition (EndMT) is a mechanism that promotes cardiac fibrosis induced by Angiotensin II (AngII).
|
29073623 |
2017 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.
|
29081650 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the constitutive and dominant negative constructs of peroxisome proliferator-activated receptor γ 3-'untranslated region (UTR), data revealed that the protective mechanism was associated with restoration of peroxisome proliferator-activated receptor γ level leading to the inhibition of angiotensin II-induced cardiac fibrosis.
|
29114000 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II) plays an important role on the pathogenesis of cardiac fibrosis.
|
29322373 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD44 Deficiency in Mice Protects the Heart Against Angiotensin Ii-Induced Cardiac Fibrosis.
|
29470359 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we found that A77 1726 treatment attenuated pressure overload or angiotensin II (Ang II)-induced cardiac hypertrophy <i>in vivo</i>, as well as agonist-induced hypertrophic response of cardiomyocytes <i>in vitro</i> In addition, we showed that A77 1726 administration prevented induction of cardiac fibrosis by inhibiting cardiac fibroblast (CF) transformation into myofibroblast.
|
29540538 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe the use a highly selective TG2 small-molecule inhibitor to test the efficacy of TG2 inhibition as an anti-fibrotic therapy for heart failure employing two different in vivo models of cardiac fibrosis: Progressively induced interstitial cardiac fibrosis by pressure overload using angiotensin II infusion: Acutely induced focal cardiac fibrosis through myocardial infarction by ligation of the left anterior descending coronary artery (AMI model).
|
29795262 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous Insl6 protein inhibits cardiac systolic dysfunction and cardiac fibrosis in angiotensin II- and isoproterenol-induced cardiac stress models.
|
29887522 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of histopathological analysis, as well as measurements of collagen expression and cardiac fibroblast proliferation indicated that puerarin administration significantly inhibited cardiac fibrosis induced by AB and AngII.
|
29928229 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glaucocalyxin A attenuates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts.
|
30072098 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the potential anti-myocardial fibrosis effect and mechanism of SalB on Angiotensin II (Ang II)-induced cardiac fibrosis in vitro.
|
30365482 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II), an effective component of renin-angiotensin system, plays a pivotal role in cardiac fibrosis, which may further contribute to heart failure.
|
30369577 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition.
|
30670148 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, we here identified irisin as a promising anti-fibrotic therapeutic for angiotensin II-related cardiac fibrosis.
|
30703374 |
2019 |